Drug intelligence / Profile preview

niantong qufeng granules

Development stage: Unknown
Lead developer: Chengdu Kangrui Pharmaceutical
Administration: Oral

Overview

Niantong Qufeng Granules (拈痛祛风颗粒) is a Traditional Chinese Medicine (TCM) compound granule developed for the treatment of acute gouty arthritis. The formulation is designed to dispel wind, eliminate dampness, and alleviate pain, targeting the inflammatory symptoms associated with gout flares. Developed by Chengdu Kangrui Pharmaceutical in collaboration with academic institutions, the drug has reached Phase III clinical trials in China to evaluate its efficacy and safety in reducing joint swelling and pain compared to standard care.

Brand names: Niantong Qufeng
Other names: 拈痛祛风颗粒Nian Tong Qu Feng granules

Targets

TNFA (Tumor necrosis factor alpha (soluble))IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on niantong qufeng granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on niantong qufeng granules.

Explore the full profile